급성 골수성 백혈병(AML) 시장 : 기회 평가, 역학, 임상시험, 미충족 요구, 예측(2032년)

Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032

US $ 9,995 ￦ 14,183,000

Zip (Single User License)

ZIP파일 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 19,990 ￦ 28,367,000

Zip (Site License)

ZIP파일 보고서를 동일 기업의 한 부서에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 29,985 ￦ 42,551,000

Zip (Global License)

ZIP파일 보고서를 동일 기업(해외)의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

급성 골수성(또는 골수원성 또는 골수구성) 백혈병(AML)은 골수 및 말초혈에서 골수계 전구세포의 이상 증식 또는 분화에 의해 발생하는 조혈계 악성 종양입니다. 희소인 혈액암임에도 불구하고 AML은 블록버스터 시장이며, 2022년 판매고 23억 달러에서 CAGR 3.7%로 확대하며, 2032년에는 37억 달러로 성장할 것으로 예측되고 있습니다. 주요 8개국의 AML에 대한 현재의 치료 패러다임은 허약한 환자에게는 Venclexta와 HMA 또는 LDAC 레지멘을 병용하고, 체력이 있는 환자에게는 7+3 화학요법을 시행하는 것에 크게 의존하고 있습니다. AML에는 치료 옵션의 확대 및 환자의 전생존 기간을 연장하기 위한 이식 결과의 개선을 요구하는 미충족 요구가 몇가지 존재합니다.

주요 8개국 시장(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본, 캐나다)에서 급성 골수성 백혈병(AML)의 위험인자, 병존 질환, 세계 및 과거의 역학 동향에 대해 설명하고, 급성 골수성 백혈병(AML)의 진단 발증례와 진단 유병률에 관한 10년간의 역학 예측 등을 정리하여 전해드립니다.

목차

제1장 서문

제2장 주요 요약

제3장 질병의 개요

• 급성 골수성 백혈병의 개요
• 급성 골수성 백혈병 시장 강점, 약점, 기회, 위협 분석
• 급성 골수성 백혈병의 분류

제4장 역학

• 급성 골수성 백혈병으로 진단된 증례 수,(남녀) 18세 이상, 2022-2032년
• 급성 골수성 백혈병 진단 증례 수의 연령별 동향(남녀), 2022년
• 급성 골수성 백혈병성 특이적 진단 증례 수,(남녀) 18세 이상, 2022년
• 급성 골수성 백혈병의 발생원과 조사 방법

제5장 현재의 치료 선택사항

• 치료 패러다임 - 제일 선택의 도입 요법
• 치료 패러다임 - 강화, 유지, 재발/난치성 치료
• 급성 골수성 백혈병의 치료 알고리즘
• 시판 제품의 개요
• 제품 개요 : 항체약물접합체(Mylotarg)
• 제품 개요 : BCL-2 저해제(Venclexta)
• 제품 개요 : FLT3 저해제(Rydapt, Vanflyta, Xospata)
• 제품 개요 : 헤지호그 경로 저해제(Daurismo)
• 제품 개요 : IDH1/2 저해제(Tibsovo, Idhifa, Rezlidhia)
• 제품 개요 : 세포치료(Omisirge)
• 제품 개요 : 저메틸화제(Dacogen, Onureg 및 Vidaza)
• 제품 개요 : 저메틸화제(Inaqovi)
• 제품 개요 : 브랜드 화학요법(Vyxeos)

제6장 미충족 요구와 기회

• 급성 골수성 백혈병에서의 미충족 요구
• 완전 관해를 지속적인 전생존 기간으로 변환
• 세컨드 라인 이후의 치료
• 치료가 어려운 환자의 치료 옵션 개선
• 환자 액세스와 HSCT 결과를 개선

제7장 연구개발 전략

• 급성 골수성 백혈병에서 임상시험 디자인의 동향
• 임상시험 스폰서별 급성 골수성 백혈병 임상시험
• 급성 골수성 백혈병에서 거래의 동향

제8장 파이프라인 평가

• AML 파이프라인의 개요
• 급성 골수성 백혈병에 대한 후기 파이프라인 약제
• 제품 개요 : 브랜드 화학요법(radgocitabine)
• 제품 개요 : E-세레크틴 저해제(uproleselan)
• 제품 개요 : FLT3 저해제(clifutinib, crenolanib, SKLB-1028)
• 제품 개요 : 저메틸화제(ASTX030)
• 제품 개요 : 메닌 저해제(revumenib, ziftomenib)
• 제품 개요 : 모노클로널 항체(magrolimab)
• 제품 개요 : 펩티드 백신(galinpepimut-S)
• 제품 개요 : 방사성 면역 복합체(요오드-131-apamistamab)
• 제품 개요 : S1PR 아고니스트(mocravimod)
• 제품 개요 : 세포치료(OmnImmune, Orca-T)

제9장 시장 전망

• 급성 골수성 백혈병 시장 예측
• 급성 골수성 백혈병 시장 촉진요인과 억제요인

제10장 부록

제11장 문의

KSA

영문 목차

영문목차

Abstract

This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Acute Myeloid Leukemia (AML).

These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData's World Markets Healthcare (WMH) and POLI Price Intelligence databases.

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Acute Myeloid Leukemia (AML). These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData's World Markets Healthcare (WMH) and POLI Price Intelligence databases.

Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. Despite being a rare blood cancer, AML is a blockbuster market and is expected to grow from sales of $2.3 billion in 2022 to $3.7 billion in 2032 at a compound annual growth rate (CAGR) of 3.7%. The current treatment paradigm for AML across the 8MM relies heavily on the use of Venclexta plus HMA or LDAC regimen for frail patients, and 7+3 chemotherapy for fit patients. There are several unmet needs in AML that call for more treatment options and improving transplant outcome for extending overall survival in patients.

Major drivers of growth in the AML market across the 8MM over the forecast period include the following -

• Approval of 14 new late-stage pipeline agents
• Pipeline agents to be used as therapies for improving HSCT outcomes are important market drivers as they create a brand-new market segment as HSCT aids
• Growing patient population to 2032

Major barriers to growth in the AML market across the 8MM over the forecast period include the following:

• Patent expiries and subsequent genericization of the most lucrative agents that are part of the standard of care, principally Roche/AbbVie's Venclexta
• Limited launches of novel pipeline agents in Asian markets
• Continued dominance of the traditional 7+3 chemotherapy regimen in the newly-diagnosed setting

Key Highlights

• Report deliverables include a Pdf and Excel-based forecast model
• Forecasts includes the 8MM
• Forecasts covers from 2022-2032
• GlobalData valued the Acute Myeloid Leukemia market in the 8MM at $2.3 billion and expects the market to increase to $3.7 billion by 2032
• Syndex Pharmaceuticals, Gamida Cell, and GlycoMimetics are expected to take market-leading position in 2032
• A high level of unmet need will remain for most Acute Myeloid Leukemia patient populations during the forecast period
• The AML late-stage R&D pipeline is diversified in addressing different pain points throughout the treatment journey

Scope

• Overview of Acute Myeloid Leukemia, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized Acute Myeloid Leukemia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Acute Myeloid Leukemia therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Acute Myeloid Leukemia treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
• Analysis of the current and future market competition in the global Acute Myeloid Leukemia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Acute Myeloid Leukemia therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Acute Myeloid Leukemia therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Abbreviations
• 1.3. Related Reports

2. Executive Summary

3. Disease Overview

• 3.1. Overview of Acute Myeloid Leukemia
• 3.2. Acute Myeloid Leukemia Market Strength, Weakness, Opportunity, and Threat Analysis
• 3.3. Classification of Acute Myeloid Leukemia

4. Epidemiology

• 4.1. Diagnosed Incident Cases of Acute Myeloid Leukemia, Both Sexes, Ages ≥18 Years, 2022-32
• 4.2. Age-Specific Trends in Diagnosed Incident Cases of Acute Myeloid Leukemia, Both Sexes, 2022
• 4.3. Sex-Specific Diagnosed Incident Cases of Acute Myeloid Leukemia, Both Sexes, Ages ≥18 Years, 2022
• 4.4. Sources and Methodology for Acute Myeloid Leukemia Incidence

5. Current Treatment Options

• 5.1. Treatment Paradigm - First-Line Induction Therapy
• 5.2. Treatment Paradigm - Consolidation, Maintenance, and Relapsed/Refractory Therapy
• 5.3. Acute Myeloid Leukemia Treatment Algorithm
• 5.4. Marketed Products Overview
• 5.5. Product Profile: Antibody-drug Conjugate (Mylotarg)
• 5.6. Product Profile: BCL-2 Inhibitor (Venclexta)
• 5.7. Product Profile: FLT3 Inhibitors (Rydapt, Vanflyta, Xospata)
• 5.8. Product Profile: Hedgehog Pathway Inhibitor (Daurismo)
• 5.9. Product Profile: IDH1/2 Inhibitors (Tibsovo, Idhifa, Rezlidhia)
• 5.10. Product Profile: Cell Therapy (Omisirge)
• 5.11. Product Profile: Hypomethylating Agents (Dacogen, Onureg, and Vidaza)
• 5.12. Product Profile: Hypomethylating Agents (Inaqovi)
• 5.13. Product Profile: Branded Chemotherapy (Vyxeos)

6. Unmet Needs and Opportunities

• 6.1. Unmet Needs in Acute Myeloid Leukemia
• 6.2. Translating Complete Remission to Durable Overall Survival
• 6.3. Treatments in the Second Line and Beyond
• 6.4. Improving Treatment Options for Difficult-to-treat Patients
• 6.5. Improving Patient Access and Outcome of HSCT

7. R&D Strategies

• 7.1. Trends in Clinical Trial Design in Acute Myeloid Leukemia
• 7.2. Acute Myeloid Leukemia Clinical Trials by Trial Sponsors
• 7.3. Trends in Deal-Making in Acute Myeloid Leukemia

8. Pipeline Assessment

• 8.1. AML Pipeline Overview
• 8.2. Late-Stage Pipeline Agents for Acute Myeloid Leukemia
• 8.3. Product Profile: Branded Chemotherapy (radgocitabine)
• 8.4. Product Profile: E-selectin Inhibitor (uproleselan)
• 8.5. Product Profile: FLT3 Inhibitors (clifutinib, crenolanib, SKLB-1028)
• 8.6. Product Profile: Hypomethylating Agents (ASTX030)
• 8.7. Product Profile: Menin Inhibitors (revumenib, ziftomenib)
• 8.8. Product Profile: Monoclonal Antibody (magrolimab)
• 8.9. Product Profile: Peptide Vaccine (galinpepimut-S)
• 8.10. Product Profile: Radioimmunoconjugate (iodine-131-apamistamab)
• 8.11. Product Profile: S1PR Agonist (mocravimod)
• 8.12. Product Profile: Cell Therapies (OmnImmune, Orca-T)

9. Market Outlook

• 9.1. Acute Myeloid Leukemia Market Forecast
• 9.2. Acute Myeloid Leukemia Market Drivers and Barriers

10. Appendix

• 10.1. Primary Research: Key Opinion Leader Information
• 10.2. Bibliography
• 10.3. About the Authors

11. Contact Us

관련자료